CHMP recommends approval of Novo Nordisk's hemophilia drug for postpartum bleeding

The European Medicines Agency expert committee, the CHMP, has recommended that the indication for Novo Nordisk’s hemophilia drug Novoseven is extended to include women suffering from severe hemorrhaging after giving birth.

Photo: Novo Nordisk / PR

On Friday, Novo Nordisk has announced that the European Medicines Agency’s (EMA) expert committee, the CHMP, has adopted a positive opinion of Novoseven as a treatment for severe postpartum hemorrhage, a company press release reports.

Heavy bleeding after birth is a leading cause of death in new mothers, Novo reports, and Novoseven’s indication will be extended to include cases ”when medications used to induce uterine contractions and reduce bleeding (uterotonics) are insufficient to stop the bleeding.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs